Web16 apr. 2024 · First-line systemic therapy for morphea includes methotrexate with or without systemic corticosteroids. When this regimen ... 36 years (interquartile range, 16-53 years) and median diagnostic delay of 8 months (interquartile range, 4-14 months). Generalized morphea (37 [48%]), pansclerotic morphea (12 [16%]), and linear … WebMorphea (syn. localized scleroderma) occurs as a result of autoimmune fibrosing (leather-like) injury to the skin and sometimes the underlying fat, muscle and bone. Morphea is sometimes referred to as “localized scleroderma”. However, despite their similar names, patients with morphea are not at increased risk of developing internal organ ...
Morphea Article - StatPearls
WebChildren and adults with active morphea (circumscribed morphea, linear scleroderma, generalised morphea, or mixed morphea) may present similar reduction in disease activity or damage with medium-dose (50 J/cm²) UVA-1, low-dose (20 J/cm²) UVA-1, or narrowband UVB phototherapy. Those treated with medium-dose (50 J/cm²) UVA-1 or low-dose (20 J ... Web20 feb. 2024 · Morphea, also called localized scleroderma, is a rare inflammatory skin condition that can also affect the subcutaneous … cardinals cowboys
Morphea (Scleroderma): Treatment, Causes, and More
Web30 okt. 2024 · Morphea research studies recruiting patients in 2024 need your help. ... Generalized Plaque Morphea: Multiple lesions join together and are more widespread. ... Treatment of generalized morphea typically involves methotrexate or steroids. However, in severe cases where the lesions develop deeper in the tissue and affect the joints, ... Webin ten juvenile patients with severe or methotrexate-resistant localized scleroderma (two with pansclerotic morphea, five with linear scleroderma and three with generalized morphea). The clinical efficacy of MMF was assessed by clinical examination and thermography. The authors demonstrated efficacy of MMF in Web20 aug. 2014 · Based upon the randomized trial findings and the subsequent long-term follow-up study, his recommendation for patients with active juvenile localized scleroderma – whether of the linear, pansclerotic, or generalized morphea subtype – is 3 months of initial bridging therapy with a combination of methotrexate plus systemic corticosteroids, … bronglais hospital trauma and orthopaedics